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Abstract
Background Membranous glomerulonephritis is typically
classified as idiopathic or secondary to systemic lupus
erythematosus (SLE), hepatitis B, drugs, toxins, other
infections, or malignancy. Not infrequently in some
patients without a definite diagnosis of SLE, pathologic
features of secondary membranous nephropathy are seen
e.g., mesangial and/or subendothelial deposits, tubulore-
ticular inclusions, and full house immunofluorescence. In
these patients, there is uncertainty about the etiology,
response to therapy, and prognosis of membranous GN.
Methods We retrospectively reviewed the charts of 98
patients with membranous GN at San Francisco General
Hospital and John Stroger Hospital of Cook County over a
10-year period. Data were collected and analyzed using
SPSS.18.
Results Thirty-nine (40 %) had idiopathic membranous
GN (Group 1), thirty-six (37 %) had lupus membranous
GN (Group 2) and twenty-three (23 %) had some patho-
logical features of secondary membranous GN, but no
definite etiology of membranous GN (Group 3). At
baseline (at time of renal biopsy) and after mean follow-
up of 3.5 years, the average serum creatinine (in mg/dL)
in Group 1 was (1.6 ± 1.0 versus 1.6 ± 1.7), Group 2
was (1.8 ± 2.5 versus 1.2 ± 0.9) and Group 3 was
(1.1 ± 0.4 versus 1.27 ± 0.83), respectively. For the
same time points, the average urine protein to creatinine
ratio (g/g) in Group 1 was (9.8 ± 7.1 versus 5.7 ± 6.7),
Group 2 was (4.2 ± 3.9 versus 1.7 ± 2.2), and Group 3
was (7.4 ± 5.7 versus 3.1 ± 3.8). In addition, during the
follow-up period, eleven of 39 (28 %) in Group 1, two of
36 (6 %) in Group 2, and three of 23 (13 %) in Group 3
progressed to end-stage renal disease and were started on
dialysis.
Conclusions It appears that patients with lupus membra-
nous GN have better renal prognosis than patients with
idiopathic membranous GN. The renal prognosis for
patients with pathological features of lupus membranous
but no diagnosis of systemic lupus (lupus-like membranous
GN) falls in between. Further studies are needed to deter-
mine if Group 3 patients can (a) definitively be classified as
true idiopathic membranous GN or lupus membranous GN
or (b) they have a separate disease from either M-type
phospholipase A2 receptor membranous nephropathy or
systemic lupus-induced membranous nephropathy.
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Introduction
More than 50 years ago, it was recognized that there are a
group of patients with membranous GN who have patho-
logical features of lupus nephritis, but not a diagnosis of
systemic lupus erythematosus (SLE). In 1964, Simenhoff
and Merrill stated that ‘‘lupus nephritis may present as a
renal syndrome only, without any of the other manifesta-
tions of SLE [1].’’ The problem with labeling these patients
as renal-limited lupus is that systemic lupus suggests a
‘systemic disease’ that is not limited to one organ. It is
likely that the pathogenesis of membranous nephropathy is
autoimmune, thus stating that these patients have renal-
limited lupus adds little to current understanding and nat-
ural history of this disease. It is true that some of the
patients labeled as ‘‘latent lupus’’ and not SLE at the time
of kidney biopsy subsequently were diagnosed with SLE
years later. However, the criteria for diagnosing SLE have
changed over the years (many of the patients with latent
lupus were diagnosed using the LE cell preps which are no
longer used), and it is not documented what percentage of
patients with pathological features of membranous lupus
nephritis but no diagnosis of SLE subsequently developed
SLE. At the time of kidney biopsy, it is important to
determine if membranous GN is primary or secondary in
nature, because pathogenesis, treatment response and
prognosis differ in each disease group. We evaluated 98
patients with membranous nephropathy and attempted to
determine renal prognosis depending on whether they have
idiopathic, lupus or ‘lupus-like’ membranous GN.
Methods
All kidney biopsy reports at San Francisco General Hos-
pital between 1998 and 2008 and at John Stroger Hospital
of Cook County in Chicago between 2001 and 2008 were
reviewed. All patients with histologic diagnosis of mem-
branous GN were selected. Only patients with membranous
lupus nephritis (class V by the ISN/RPS 2003 classifica-
tion) were included for analysis; those with class V and
concurrent class III or class IV lupus nephritis were
excluded. Subsequently, the electronic medical records of
31 patients with membranous GN at San Francisco General
Hospital and 67 patients at John Stroger Hospital of Cook
County were reviewed. The patients were then divided into
3 groups. Group 1: idiopathic membranous GN with no
pathological features of secondary membranous GN,
Group 2: membranous lupus nephritis by both clinical and
pathologic criteria, Group 3: ‘‘lupus-like’’ membranous GN
in which pathological features of membranous lupus
nephritis are present without a clinical diagnosis of SLE.
The pathological features of membranous lupus nephritis
included a combination of mesangial deposits, subendo-
thelial deposits, mesangial hypercellularity, tubuloreticular
inclusions, intense C1q staining on immunofluorescence
microscopy and/or full house immunofluorescence pattern,
and tubular basement membrane deposits (Fig. 1). The
pathological features were enough to make the pathologist
comment on the report that systemic lupus should be ruled
out. IgG subclass staining was performed for IgG1, IgG2,
IgG3, and IgG4 using primary antibody (Invitrogen) dilu-
tions at 1:120, 1:120, 1:60, and 1:120, respectively. Sec-
ondary FITC-labeled goat anti-mouse IgG antibody
(Invitrogen) was used at 1:80 dilution for antigen detection.
Baseline medical history and laboratory results, treat-
ment administered and long-term follow-up laboratory
results were collected on all patients. Collected data were
analyzed using SPSS.18 software. For quantity variables,
we used ANOVA to determine statistically significance
differences (p value\0.05) between means of the groups
for both baseline and follow-up characteristics. To compare
means in two groups, we used Post Hoc Tukey method.
Also to compare between two quality variables, we used
the Chi-Square test.
This study was approved by the local ethics committee
(institutional review board) and need for informed consent
was waived (#13- 11936).
Results
Of the 98 patients, 39 (40 %) had idiopathic membranous
GN, 36 (37 %) had membranous lupus nephritis, and 23
(23 %) had ‘‘lupus-like’’ membranous GN (Table 1). The
incidence of idiopathic membranous GN, membranous
lupus nephritis, and ‘‘lupus-like’’ membranous GN was 36,
36, and 29 % at South Francisco General Hospital and 42,
37, and 21 % at Stroger Hospital, respectively.
The baseline characteristics of patients with idiopathic
membranous GN, membranous lupus nephritis, and
‘‘lupus-like’’ membranous GN are summarized in Table 2.
Patients with idiopathic membranous GN were signifi-
cantly older than patients with membranous lupus nephritis
or ‘‘lupus-like’’ membranous GN (46 versus 37 versus
38 years, respectively). Gender ratio was [2:1 favoring
men with idiopathic membranous GN, and reversed to
almost 2:1 favoring women with membranous lupus
nephritis, and equal in patients with ‘‘lupus-like’’ mem-
branous GN. There were more Asians and less Hispanics
and Whites with membranous lupus nephritis compared to
idiopathic membranous GN. The baseline Creatinines for
Groups 1, 2, 3 were 1.6, 1.8, and 1.1 mg/dL, respectively.
Patients with idiopathic membranous GN had more base-
line proteinuria (9.8 g/d) compared to patients with lupus
membranous GN (4.2 g/d) and ‘‘lupus-like’’ membranous
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GN (7.4 g/d). All the patients in the membranous lupus
nephritis group tested positive for ANA at least on one
occasion, whereas ANA positivity was 27 % in the idio-
pathic membranous GN group and 52 % in the ‘‘lupus-
like’’ membranous GN group. Only three patients out of the
entire cohort tested positive for hepatitis B (3 %). By
comparison, 7 out of 101 (6.9 %) of our current dialysis
patients were positive for hepatitis B. Because the inci-
dence of hepatitis B was the same in patients with mem-
branous nephropathy and our dialysis patients (who did not
have membranous nephropathy), we do not believe hepa-
titis B was causative of the membranous nephropathy in
these patients. Hepatitis C was seen frequently in our
patients, consistent with the high incidence of hepatitis C in
the two County hospitals. Again, 13 out of the 98 (13 %)
patients with membranous nephropathy had hepatitis C,
this compares with 24 out of 101 (23.8 %) of our dialysis
patients who were positive for hepatitis C. The corre-
sponding numbers for HIV positivity were 4/98 (4 %) for
membranous nephropathy and 6/96 (6.3 %) for dialysis
patients. The average serum albumin and serum cholesterol
concentrations were 2.5, 2.4, 2.5 g/dL, and 317, 226, and
272 mg/dL in idiopathic membranous GN, membranous
lupus nephritis, and ‘‘lupus-like’’ membranous GN groups,
respectively. To summarize, patients with idiopathic
membranous had more proteinuria and higher cholesterol
levels at baseline compared to patients with membranous
lupus nephritis.
The follow-up data are summarized in Table 3. In
general, patients with idiopathic membranous GN were
treated more often with ACEI, ARB, cyclosporine, and
cyclophosphamide, whereas patients with membranous
lupus nephritis received more prednisone, mycophenolate,
and azathioprine. The lupus-like patients also received
ACEI, ARB, and prednisone with some patients receiving
additional agents. The average serum creatinine after an
average of 3.5 years of follow-up was 1.6, 1.2, and 1.3 mg/
dL in idiopathic membranous GN, membranous lupus
nephritis, and ‘‘lupus-like’’ membranous GN groups,
respectively. The average proteinuria after 3.5 years of
follow-up was 5.7, 1.7, and 3.1 g/d, respectively, showing
statistically significant difference between the idiopathic
F 
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Fig. 1 Representative pictures of two patients with lupus-like membranous nephropathy. In a electron micrograph is shown with lots of
mesangial deposits. b shows immunofluorescence of another patient with positivity for IgG, IgM, C3, and IgA
Table 1 Incidence of primary versus secondary membranous nephropathy
Type of membranous GN SFGH
# of cases (% of total)
CCH
# of cases (% of total)
Total
# of cases (% of total)
Idiopathic membranous (Group 1) 11 (35.5 %) 28 (41.8 %) 39 (39.8 %)
Lupus membranous (Group 2) 11 (35.5 %) 25 (37.3 %) 36 (36.7 %)
Lupus-like membranous (Group 3) 9 (29.0 %) 14 (20.9 %) 23 (23.5 %)
SFGH San Francisco General Hospital, CCH Cook County Hospital
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membranous GN and the other 2 groups. The average
serum albumin after 3.5 years of follow-up was 3.5, 3.6,
and 3.5 g/dL, respectively. Thus, it seems that after an
average follow-up of 3–4 years, the average proteinuria
and serum creatinine were lower in patients with mem-
branous lupus nephritis than in those with idiopathic
membranous GN, and the patients with ‘‘lupus-like’’
membranous GN fell in between these values.
Five of the patients with ‘‘lupus-like’’ membranous GN
had IgG subclass staining, of which four had strongest
staining with IgG4 and one patient had IgG1 (Table 4). The
staining pattern was mainly around capillary loops,
although some mesangial staining was also present. None
of the patients in the lupus-like group went on to have a
definite diagnosis of systemic lupus; however, a few of
these patients who were ANA negative at the beginning
went on to develop ANA positivity. Eleven of 39 (28 %)
patients in the idiopathic membranous GN group, two of 36
(6 %) patients in the lupus membranous GN group, and
three of 23 (13 %) patients in the lupus-like membranous
GN group progressed to ESRD and were started on chronic
Table 2 Summary of baseline characteristics of the 3 groups of patients
Characteristic Group 1 Group 2 Group 3 p value
Idiopathic membranous Lupus membranous Lupus-Like membranous
Age 45.9 ± 10.3 37.0 ± 11.7 38.2 ± 11.4 0.001
Sex 28 M, 11 F 13 M, 22 F 10 M, 12 F 0.008
Race 19 AA, 14 H, 4 W, 2 Asian 18 AA, 9H, 8 Asian, 0 W 9 AA, 10 H, 2 Asian, 2 W 0.35
Cr (mg/dL) 1.57 ± 1.04 1.79 ± 2.52 1.07 ± 0.40 0.26
Prot./cr (g/g) 9.8 ± 7.1 4.2 ± 3.9 7.4 ± 5.7 0.001
ANA 9?, 25- 34?, 1- 7?, 12- 0.001
DsDNA 0?, 7- 19?, 15- 2?, 8- 0.006
Anti-Smith 1?, 2- 17?, 15- 1?, 5- 0.286
SSA 1?, 1- 15?, 16- 1?, 4- 0.67
SSB 0?, 2- 4?, 28- 1?, 4- 0.78
RNP 2?, 1- 26?, 5- 4?, 2- 0.62
Hep B/Hep C/HIV 2 Hep B, 7 Hep C, 2 HIV 1 Hep B, 3 Hep C, 1 HIV 0 Hep B, 3 Hep C, 1 HIV 0.92
Alb (g/dL) 2.5 ± 0.6 2.4 ± 1.1 2.5 ± 1 0.97
Chol (mg/dL) 316.6 ± 14.9 226.3 ± 81.8 271.7 ± 174.7 0.019
M male, F female, AA African American, W white, H hispanic, Cr creatinine, Prot./Cr urine protein/creatinine ratio
Table 3 Summary of follow-up data on the 3 groups of patients
Follow-up data Group 1 Group 2 Group 3 p value
Idiopathic membranous Lupus membranous Lupus-like membranous
Last Creatinine (mg/dL) 1.63 ± 1.66 1.17 ± 0.94 1.27 ± 0.83 0.35
Years after biopsy 3.0 ± 2.5 4.2 ± 2.7 3.5 ± 2.8
Last Albumin(g/dL) 3.45 ± 0.91 3.61 ± 0.80 3.52 ± 0.83 0.82
Years after biopsy 3.5 ± 2.7 4.6 ± 3.1 3.4 ± 3.3
Last Prot./cr (g/g) 5.73 ± 6.73 1.69 ± 2.20 3.13 ± 3.83 0.004
Years after biopsy 3.2 ± 2.5 3.8 ± 2.5 2.9 ± 1.9
Treatment data 13Pred, 26ACE, 11ARB,
10cyclos, 8cytoxan, 2MMF, 1Aza
33Pred, 15ACE, 5ARB, 2 cyclos,
6cytoxan, 13MMF, 8Aza
6Pred, 14ACE, 4ARB, 2cyclos,
2cytoxan, 2MMF, 1Aza
Dialysis patients were assumed to have a serum creatinine of 8.0 mg/dL
Pred prednisone, ACE angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, MMF mycophenolate, Aza azathioprine,
Prot./cr. urine protein/creatinine ratio
Table 4 IgG subclass staining in 5 patients with lupus-like mem-
branous nephropathy
Patient
#
IgG1 IgG2 IgG3 IgG4
6 0 0 0 1?
23 2? Tr? Tr? 1?
1 Tr? 2? 0 3?
20 0 Tr? Tr? 3?
13 0 1? 0 3?
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dialysis during the follow-up period. The 3 patients (7.6 %)
who died were in the idiopathic membranous GN group.
Discussion
At times in patients with nephrotic syndrome due to
membranous GN, histologic findings of membranous lupus
nephritis are present without the clinical diagnosis of sys-
temic lupus erythematosus (SLE). In 1976, Libit et al.
described three such pediatric patients who subsequently
developed SLE after an average follow-up of 2.2 years [2]
and the term latent lupus has been used to describe these
patients. To our knowledge, there have only been 21
patients described in the literature with latent lupus (10
female, 5 male, and six unknown gender). Their average
age was 24.7 years and follow-up was 2.3 years (data were
available in 16 patients). Additional data were available in
seven of the patients, three had complete remission, two
had partial remission, one died, and one developed renal
failure [1–8]. In 1983, Jennette et al. [9] established the
pathological findings most often seen in membranous lupus
nephritis by examining kidney biopsies of 170 patients
with membranous GN (including both patients with
established diagnosis of SLE and those with idiopathic
membranous GN). Many of the patients with features of
membranous lupus nephritis did not have systemic features
at the time of kidney biopsy. It is not clear what proportion
of these patients progressed to full-blown SLE, although
some of them did develop SLE later. Review of the liter-
ature indicates that of 77–95 such patients, 21 (25 %)
developed SLE after a mean follow-up period of 5 years
(Table 5) [7–11]. In addition, the diagnostic criteria for
SLE have changed since the publication of many of these
papers. In fact, many of the patients previously described in
the literature with latent lupus were subsequently diag-
nosed with systemic lupus using the LE cell preps, which is
no longer a common practice.
The percentage of all the cases of membranous GN
caused by membranous lupus nephritis varies between the
different studies, although the average of these studies is
24 % while 62 % were idiopathic membranous GN [9, 12–
19]. There were 1368 patients with membranous GN in all
of these studies. Other secondary causes accounted for
another 14 % of membranous GN cases. Interestingly, in
one Chinese study of 390 patients with membranous
nephropathy, 12.1 % of the patients had hepatitis B, which
is close to the 11 % incidence of hepatitis B in the general
Chinese population [13, 20]. In the same study, the inci-
dence of malignancy-associated membranous nephropathy
was 3.1 %, which is somewhat lower than the 8.4 %
incidence found by Burstein et al. in 1993 [13, 21]. Thus,
even though hepatitis B and malignancy are likely impli-
cated in membranous GN, it should be emphasized that
they are uncommon causes (more often association rather
than true causation), whereas SLE is a common cause of
membranous GN.
In recent years, IgG subclass staining has been used to
classify the different types of membranous GN. With idi-
opathic membranous GN, IgG4 clearly predominates. On
the other hand, with membranous lupus nephritis and
malignancy-associated membranous GN, although a large
amount of IgG4 staining is present, significant IgG3
staining is detected with membranous lupus nephritis and
IgG1 and IgG2 staining is often seen in malignancy-asso-
ciated membranous GN [18, 22, 23]. When the kidney
biopsy of five of our patients with ‘‘lupus-like’’ membra-
nous GN was stained for IgG subclass, four had strong
IgG4 staining, while one had strong IgG1 staining. Thus,
the IgG subclass staining in most of these patients was
consistent with idiopathic membranous GN.
The classification of membranous GN into idiopathic
and secondary causes is only important if there is a dif-
ference in the prognosis or response to therapy in the two
groups. There are few studies on this topic and none
comparing the two groups in the same population of
patients. To get some perspective on this, we summarized
the treatment data for idiopathic membranous GN and
membranous lupus nephritis from a number of studies
(Table 6). We found that in patients with idiopathic
membranous GN, 21 % of patients that were not treated
had partial or complete remission of proteinuria, 81 % of
patients treated with cyclosporine had partial or complete
remission, and 61 % of patients treated with cytotoxic
Table 5 Prevalence of latent
lupus among patients with
membranous nephropathy and
pathology suggesting systemic
lupus
NA not available, TRI tubulo-
reticular inclusions
Study # of
patients
# developing
lupus
% developing
lupus
Follow-up
period
Pathologic
abnormality
Jennette [9] 16–34 6 18–37 % 1 year Mixture
Adu [7] 10 4 40 % 14 years Mixture
Gianviti [10] 4 1 25 % 5.8 years Full house
Yang [11] 36 9 25 % NA TRI
Wen [8] 11 1 9 % 2 years Full house
Summary 77–95 21 22–27 % 5 years
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agent plus prednisone had partial or complete remission
[24–29]. The studies on membranous lupus nephritis used
different immunosuppressive agents and the response rate
for proteinuria remission was 66 % [30–33]. The incidence
of renal failure in patients with idiopathic membranous GN
was 13 % when treated with cyclosporine and 16 % when
treated with combination cytotoxic agent and prednisone.
In patients with membranous lupus nephritis, the incidence
of renal failure was 10 %. However, this data have limi-
tations due to different time periods, different geographic
locations with different patient populations, and different
duration of follow-up, etc.
To compare the prognosis of idiopathic membranous
GN, membranous lupus nephritis, and ‘‘lupus-like’’
membranous GN, we evaluated all the patients with
membranous GN in the two county hospitals over a 10-year
period. At baseline, patients with idiopathic membranous
GN were older and more often men compared to patients
with membranous lupus nephritis. They also had more
proteinuria and higher serum cholesterols than patients
with membranous lupus nephritis. Patients with ‘‘lupus-
like’’ membranous GN had baseline characteristics some-
where in between the other two groups. At the end of
follow-up, 28 % of patients in the idiopathic membranous
GN group, 6 % in the membranous lupus nephritis group,
and 17 % in the ‘‘lupus-like’’ membranous GN group were
on dialysis. The serum creatinine and proteinuria were also
higher in patients with idiopathic membranous GN versus
Table 6 Summary of some
studies on prognosis and
response to treatment of
idiopathic membranous and
lupus membranous nephropathy
Author
Idiopathic/
Lupus
Year Drug used # of
patients
% having
remission
% with renal
failure
Follow-up
Ponticelli [24]
Idiopathic
1989 Prednisone
chlorambucil
81 Control (23 %)
Treated (67 %)
Control (49 %)
Treated (10 %)
2–11 years
Guasch [25]
Idiopathic
1992 Cyclosporine 14 71 % 29 % 12 weeks
Cattran [26]
Idiopathic
2001 Cyclosporine
Prednisone
51 Control (22 %)
Treated (75 %)
Control (9 %)
Treated (7 %)
78 weeks
Yao [27]
Idiopathic
2001 Cyclosporine 30 Control (13 %)
Treated (80 %)
0 % 15 months
Alexopoulos
[28]
Idiopathic
2006 Cyclosporine
Prednisone
51 84 % 0 % 12 months
Goumenos
[29]
Idiopathic
2007 Prednisone
Cyclosporine
Cytoxan
77 Cyclosporin
(85 %)
Cytotoxic
(55 %)
Cyclosp (26 %)
Cytotoxic
(23 %)
Summary
Idiopathic
Prednisone
Cyclosporine
Cytoxan/
Chlorambucil
304 Control (21 %)
Cyclosp. (81 %)
Cyt./chlor.
(61 %)
Control (34 %)
Cyclosp. (13 %)
Cyt./chlor.
(16 %)
3.0 years
Donadio [30]
Lupus
1977 Steroids 28 Control (40 %)
Treated (17 %)
3.6 % 0.16–10 years
Sloan [31]
Lupus
1996 Steroids
Cytoxan
Azathioprine
51 37 % 14 % 5.8 years
Sun [32]
Lupus
2008 Steroids
Chinese herb
Cyclosporine
MMF,
Cytoxan
100 87 % 7.3 % 77.6 months
Mok [33]
Lupus
2009 Steroids
Azathioprine
38 89 % 16 % 12 years
Summary
Lupus
Steroids
Other
Immunosupp.
217 Treated (66 %) 10 % 7.8 years
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patients with membranous lupus nephritis. Again, patients
with ‘‘lupus-like’’ membranous GN had values between the
other two groups. Thus, from this data, it seems membra-
nous lupus nephritis is a more benign kidney disease and/or
more responsive to treatment than idiopathic membranous
GN. Patients without a diagnosis of SLE at the time of
biopsy, but have one or more features of membranous
lupus nephritis on kidney biopsy, have an intermediate
prognosis. The question is whether some of these patients
have membranous lupus nephritis and others have idio-
pathic membranous GN or did they have an undiagnosed
disease that is separate from membranous lupus nephritis
and idiopathic membranous GN. Since only 25 % of
patients with ‘‘lupus-like’’ membranous GN described in
the literature eventually developed SLE, it is unlikely that
the etiology of the membranous GN in most of these
patients is due to either idiopathic membranous GN or
membranous lupus nephritis. However, a number of these
patients would be reclassified if they were tested for the
M-type phospholipase A2 receptor antibody.
In 2009, a seminal paper was published describing
M-type phospholipase A2 receptor as the target antigen in
idiopathic membranous GN [34]. The authors found that
70 % of patients with idiopathic membranous GN had
antibodies to this antigen as the likely causative agent for
membranous GN. The discovery of the culprit antigen in
most cases of idiopathic membranous GN (if and when it is
available for widespread use) may make it necessary to
redefine our nomenclature for membranous GN. The sub-
group of idiopathic membranous GN patients who have
antibodies to M-type phospholipase A2 receptor should be
classified as a distinct entity. The patients with a clear
cause for secondary membranous GN should be classified
as such. Future research may reserve the term idiopathic
membranous GN only for patients who are M-type phos-
pholipase A2 receptor antibody negative and have no clear
cause for secondary membranous GN. This new classifi-
cation may help in the design of future research in patients
with membranous GN.
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